Physician profile
Roy D Ary
NPI 1639100712
$748.69
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $98.26 · 2023: $275 · 2024: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $650.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $650.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $181.11 | 2023-2024 | Brixadi |
| Indivior INC. | $175.83 | 2022-2024 | Sublocade |
| Janssen Pharmaceuticals, INC | $145.79 | 2023-2024 | Spravato |
| Alkermes, INC. | $83.48 | 2023-2024 | Vivitrol, Vivitrol |
| Neurocrine Biosciences, INC. | $66.57 | 2023 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $32.58 | 2023-2024 | Austedo Xr |
| Gilead Sciences, INC. | $17.18 | 2023 | Epclusa |
| Orexo US, INC. | $16.57 | 2023 | Zubsolv |
| Boston Scientific Corporation | $15.03 | 2023 | Spectra Wavewriter |
| Otsuka America Pharmaceutical, INC. | $14.55 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Ary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.